Ignite Creation Date:
2024-05-05 @ 5:19 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00435916
Status:
COMPLETED
Last Update Posted:
2015-01-07
First Post:
2007-02-14
Brief Title:
Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma
Sponsor:
Seagen Inc
Organization:
Seagen Inc
Study Overview
Official Title:
A Phase II Study of SGN-40 Anti-huCD40 mAb in Patients With Relapsed Diffuse Large B-Cell Lymphoma DLBCL
Status:
COMPLETED
Status Verified Date:
2014-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase II open-label multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None